



Living Cell Technologies Limited

PO Box 3014

Auburn VIC 3123

ABN: 14 104 028 042

LCT appoints David Brookes as independent Director to the Board

ASX Announcement –23 August 2007, Melbourne, Australia:

Living Cell Technologies Limited (ASX:LCT, OTC: LVCLY) today announced the appointment of Dr David Brookes, as an independent Director to the Board.

Dr Brookes will replace Mr Charles Macek, who has indicated that he will shortly be resigning from the Board.

LCT Chairman Mr Simon O'Loughlin said Dr Brookes' addition to the Board provided strengths in investor relations and medical input to the company.

"David Brookes' knowledge and credibility in the Australian life science market, as well as experience as a practitioner in medicine (particularly in paediatrics), will be a strong support for the company during its clinical trials and capital raising requirements," said Mr O'Loughlin.

Dr Brookes is a Fellow of the Australian College of Rural and Remote Medicine. He currently works as a general medical practitioner in Adelaide and has worked as a biotechnology investment analyst since the 1990's. He is chairman of NSX listed company Innovance Ltd.

"I've closely followed LCT since it listed in Australia and am looking forward to being involved at this exciting and critical time in LCT's development," said Dr Brookes.

Contact:

Dr Paul Tan
Chief Executive Officer
Mob: +61 402 716 984
Dir: +64 9 270 7941

Paris Brooke
General Manager (AUS)
Mob: +61 407 715 574
Tel: +61 3 9886 0247

About Living Cell Technologies: www.lctglobal.com

Living Cell is developing live cell therapy products to treat life threatening human diseases. The company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with type 1 diabetes, the company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For the treatment of Huntington's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. Living Cell also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT has a US American Depository Receipt program, enabling US residents to purchase LCT stock. *To purchase ADRs in LCT, please contact your broker (OTC: LVCLY, CUSIP Number: 53838R107). More information about investing in the LCT ADR program can be obtained directly from Violet Pagan, Vice President Depository Receipts at the Bank of New York, by email : vpagan@bankofny.com .*

LCT disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding the approval and commercialization of product candidates could be affected by, among other things, unexpected clinical trial results; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.